Targeting Interleukin-1 and Interleukin-6: The Time Has Come to Aggressively Address Residual Inflammatory Risk. Ridker PM. J Am Coll Cardiol 2020;76:1774-1776.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ridker PM. Targeting Interleukin-1 and Interleukin-6: The Time Has Come to Aggressively Address Residual Inflammatory Risk. J Am Coll Cardiol 2020;76:1774-1776.
PMID: 33032739